News &amp; Updates

Hypertension and diabetes in midlife have been associated with increased risk of early-onset dementia, specifically the non-Alzheimer’s type, in a population-based case-control study.

Cardiometabolic diseases may serve as clinical markers for early-onset dementia

Achieving transfusion independence with first-line luspatercept in a patient with LR-MDS–associated anaemia

18 Aug 2026 by

An 84-year-old man presented with a 2-year history of chronic anaemia (haemoglobin [Hb], 10–11 g/dL) in December 2024. His anaemia progressively worsened, with Hb dropping to a nadir of 7.5 g/dL. He reported stable angina and reduced exercise tolerance, with an ability to walk only on level ground and inability to climb stairs. His medical history included ischaemic heart disease, hypertension, hypothyroidism, and mild cytopenia.

Achieving transfusion independence with first-line luspatercept in a patient with LR-MDS–associated anaemia

[Infographics] ARNI for hypertension: Clinical trial data & Asian guideline recommendations

18 Aug 2026 by

The Japanese Society of Hypertension Guidelines 2025 recommend angiotensin receptor–neprilysin inhibitor (ARNI) as step 2 or step 3 treatment, highlighting its role in hypertension management in patients with comorbidities, including cardiac hypertrophy, chronic kidney disease and heart failure. Data from clinical trials, including those conducted in Asians, support these recommendations.

[Infographics] ARNI for hypertension: Clinical trial data & Asian guideline recommendations

Regulatory approval delays for pembrolizumab & T-DXd in APAC highlight need for benefit-based prioritization

18 Aug 2026 by

A study conducted by the Asia-Pacific Oncology Drug Development Consortium finds substantial variability in regulatory approval delays of pembrolizumab and trastuzumab deruxtecan (T-DXd) across 10 Asia-Pacific (APAC) territories, and a lack of consistent prioritization of high-incidence tumours, high clinical benefit scores or curative treatment intent.

Regulatory approval delays for pembrolizumab & T-DXd in APAC highlight need for benefit-based prioritization

Gefurulimab for AChR-Ab–positive gMG succeeds in phase III trial

Gefurulimab, a novel bispecific nanobody that targets complement factor 5 (C5) delivers rapid and sustained clinical benefit in patients with anti–acetylcholine receptor antibody–positive (AChR-Ab+) generalized myasthenia gravis (gMG), as shown in the phase III PREVAIL trial.

Gefurulimab for AChR-Ab–positive gMG succeeds in phase III trial

Tim-3 blockade controls tumour growth in metabolic liver cancer

In patients with steatohepatitis-related hepatocellular carcinoma (HCC), Tim-3 plays a key role in regulating dendritic cell (DC) ferroptosis, with its expression predicting poor prognosis, suggests a study.

Tim-3 blockade controls tumour growth in metabolic liver cancer

Second-line adagrasib plus cetuximab falls short of extending survival in KRAS G12C-mutated mCRC

Second-line treatment with adagrasib plus cetuximab demonstrates manageable safety but results in no statistically significant improvement in both progression-free (PFS) and overall survival (OS) in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) compared with chemotherapy, results of the KRYSTAL-10 trial have shown.

Second-line adagrasib plus cetuximab falls short of extending survival in KRAS G12C-mutated mCRC

17 Aug 2026

Nicotinamide supplementation boosts human-milk vitamin B3 concentrations

Lactating women with no nicotinamide supplementation tend to have human-milk total vitamin B3 concentrations below the fifth percentile reference limit, a Tanzania study has found.

Nicotinamide supplementation boosts human-milk vitamin B3 concentrations

Kids with CAH exhibit distinct, age-dependent developmental deficits

In a cross-sectional study, children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency show distinct developmental challenges at different ages.

Kids with CAH exhibit distinct, age-dependent developmental deficits

Lower risk of asthma exacerbation with GLP-1 RA vs DPP-4i in patients with DM